CLINICAL INDICATIONS FOR THE USE OF NITROGEN MUSTARD AND TRIETHYLENE MELAMINE IN MALIGNANT LYMPHOMAS AND LEUKEMIAS
- 1 April 1958
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 68 (3) , 974-978
- https://doi.org/10.1111/j.1749-6632.1958.tb42653.x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- The pathogenesis and management of neurological complications in patients with malignant lymphomas and leukemiaCancer, 1958
- Clinical Trials of p-(Di-2-chloroethylamine)-phenylbutyric Acid (CB 1348) in Malignant LymphomaBMJ, 1955
- Recent Advances in the Management of Lymphomas and LeukemiasMedical Clinics of North America, 1953
- MYLERAN IN CHRONIC MYELOID LEUKÆMIA RESULTS OF TREATMENTThe Lancet, 1953
- The Clinical Use of Triethylene MelamineBlood, 1952
- Triethylene Melamine in the Treatment of Neoplastic DiseaseBlood, 1952
- TRIETHYLENE MELAMINE IN THE TREATMENT OF NEOPLASTIC DISEASEA.M.A. Archives of Internal Medicine, 1951
- NITROGEN MUSTARD THERAPYJAMA, 1946
- NITROGEN MUSTARDS IN THE TREATMENT OF NEOPLASTIC DISEASEJAMA, 1946
- The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and SulfidesScience, 1946